RT Journal Article
SR Electronic
T1 Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.13.20094193
DO 10.1101/2020.05.13.20094193
A1 Min Seo Kim
A1 Soon-Woo Jang
A1 Yu-Kyung Park
A1 Bong-Ok Kim
A1 Tae-Ho Hwang
A1 Seok Ho Kang
A1 Won Jun Kim
A1 Hea-Woon Park
A1 Wonjong Yang
A1 Joonyoung Jang
A1 Min Ho An
YR 2020
UL http://medrxiv.org/content/early/2020/05/18/2020.05.13.20094193.abstract
AB Background No consensus or evidence-based guideline currently exists for pharmacological therapy against Coronavirus Disease 2019 (COVID-19). While South Korea has been relatively successful in managing the pandemic, its management of confirmed cases and treatment outcomes have not been reported to date.Methods A retrospective cohort study of the 358 laboratory-confirmed SARS-CoV-2 - or COVID-19 - patients was conducted. Of these patients, 270 adult patients met inclusion criteria and were included in our analyses. The primary endpoints were time to viral clearance and clinical improvement. The mean duration to viral clearance and clinical improvements were displayed as bar-plots to visualize treatment responses.Results Ninety-seven moderate COVID-19 patients were managed with hydroxychloroquine (HQ) plus antibiotics (n = 22), lopinavir-ritonavir (Lop/R) plus antibiotics (n = 35), or conservative treatment (n = 40). Time to viral clearance, as signified by negative conversion on PCR, after initiation of treatment was significantly shorter with HQ plus antibiotics compared to Lop/R plus antibiotics (hazard ratio [HR], 0.49; 95% confidence interval [95% CI], 0.28 to 0.87) or conservative treatments (HR, 0.44; 95% CI, 0.25 to 0.78). Hospital stay duration after treatment was also shortest for patients treated with HQ plus antibiotics compared to other treatment groups. Subgroup analysis revealed that mean duration to viral clearance was significantly reduced with adjunctive use of antibiotics compared to monotherapy (HR 0.81, 95% CI, 0.70 to 0.93). While both HQ and Lop/R showed side effects including nausea, vomiting, and elevation of liver transaminases, none were serious.Conclusion This first report on pharmacological management of COVID-19 from South Korea revealed that HQ with antibiotics was associated with better clinical outcomes in terms of viral clearance, hospital stay, and cough symptom resolution compared to Lop/R with antibiotics or conservative treatment. The effect of Lop/R with antibiotics was not superior to conservative management. The adjunct use of the antibiotics may provide additional benefit in COVID-19 management but warrants further evaluation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo supported fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA retrospective cohort study of the 358 laboratory confirmed SARS CoV 2 infected patients hospitalized in Korea Worker’s Compensation & Welfare Service Daegu Hospital was conducted.